Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy

被引:12
|
作者
Cripe, Linda H. [1 ]
Barber, Brent J.
Spicer, Robert L.
Wong, Brenda L.
Weidner, Norbert
Benson, D. Woodrow
Markham, Larry W.
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Cardiol, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA
[5] Univ Arizona, Coll Med, Div Cardiol, Tucson, AZ USA
关键词
inotropes; dobutamine; milrinone; Duchenne muscular dystrophy;
D O I
10.1016/j.nmd.2006.07.021
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report the use of continuous intravenous inotrope infusion as a palliative management strategy for the treatment of symptomatic, refractory, end stage cardiac dysfunction in patients with Duchenne muscular dystrophy. Milrinone and/or dobutamine administered by continuous intravenous infusion provided symptomatic and objective cardiovascular improvement up to 30 months in 3 individuals with Duchenne muscular dystrophy and severe dilated cardiomyopathy. Continuous inotrope infusion should be considered a practical treatment strategy for end stage cardiac dysfunction in Duchenne muscular dystrophy patients when cardiac transplantation is not a viable option. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:745 / 748
页数:4
相关论文
共 50 条
  • [1] Geographic variation in the use of continuous outpatient inotrope infusion therapy and beta blockers
    Grazette, Luanda
    Tran, Jeffrey S.
    Zawadzki, Nadine K.
    Zawadzki, Roy S.
    McLeod, Jennifer M.
    Fong, Michael W.
    Wilson, Melissa L.
    Havakuk, Ofer
    Hay, Joel W.
    IJC HEART & VASCULATURE, 2022, 39
  • [2] Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy
    Dorin Sumanaru
    Loic Josseran
    Aben Essid
    Blaise Mbieleu
    Isabelle Haegy
    Jean Bergounioux
    Pediatric Cardiology, 2019, 40 : 668 - 670
  • [3] Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy
    Sumanaru, Dorin
    Josseran, Loic
    Essid, Aben
    Mbieleu, Blaise
    Haegy, Isabelle
    Bergounioux, Jean
    PEDIATRIC CARDIOLOGY, 2019, 40 (03) : 668 - 670
  • [4] Use of advanced heart failure therapies in Duchenne muscular dystrophy
    Wittlieb-Weber, Carol A.
    Villa, Chet R.
    Conway, Jennifer
    Bock, Matthew J.
    Gambetta, Katheryn E.
    Johnson, Jonathan N.
    Lal, Ashwin K.
    Schumacher, Kurt R.
    Law, Sabrina P.
    Deshpande, Shriprasad R.
    West, Shawn C.
    Friedland-Little, Joshua M.
    Lytrivi, Irene D.
    McCulloch, Michael A.
    Butts, Ryan J.
    Weber, David R.
    Knecht, Kenneth R.
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2019, 53 : 11 - 14
  • [5] Which place for ivabradine in Duchenne muscular dystrophy with heart failure?
    Fayssoil, Abdallah
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 768 - 769
  • [6] Duchenne Muscular Dystrophy: the Heart of the Matter
    Jeffrey A. Shih
    Alejandro Folch
    Brenda L. Wong
    Current Heart Failure Reports, 2020, 17 : 57 - 66
  • [7] Duchenne Muscular Dystrophy: the Heart of the Matter
    Shih, Jeffrey A.
    Folch, Alejandro
    Wong, Brenda L.
    CURRENT HEART FAILURE REPORTS, 2020, 17 (03) : 57 - 66
  • [8] Gene therapy for Duchenne muscular dystrophy
    Suzuki, Naoki
    Miyagoe-Suzuki, Yuko
    Takeda, Shin'ichi
    FUTURE NEUROLOGY, 2007, 2 (01) : 87 - 96
  • [9] Gene therapy for Duchenne muscular dystrophy
    Ramos, Julian
    Chamberlain, Jeffrey S.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1255 - 1266
  • [10] Gene therapy for Duchenne muscular dystrophy
    Verhaart, Ingrid E. C.
    Aartsma-Rus, Annemieke
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (05) : 588 - 596